SPECTACLE LENSES FB Twitter LinkedIn

SPECTACLE LENSES

Spectacles accounted for over 55% of the overall global eyewear market in 2016, a market projected to reach US$165 billion by 2022.1
 

By the year 2050 around 50% of the world’s population will have myopia (almost 5 billion people) and in some Asian countries the prevalence is projected to reach almost 70%.2 Based on the projected increase in the prevalence of myopia, and the associated complications with myopia, much research has focused on slowing down myopia progression with spectacle or contact lenses.

Such studies have primarily assessed the efficacy of spectacle and contact lenses designed to reduce relative peripheral hyperopic defocus or accommodative lag. While, on average, contact lenses have shown a reduction of myopia progression of about 30-40%, the reduction with spectacle lenses is only about 10-20% (higher in subgroups).

However, myopia control is primarily initiated in children and many parents prefer their children to wear spectacle lenses rather than contact lenses, not only due to safety concerns, but also because often they are more familiar with the use of spectacle lenses.

Novel spectacle lenses for myopia control

Spectacle lenses currently used for myopia control reduce either relative peripheral hyperopic defocus or central hyperopic defocus during near viewing (i.e. accommodative lag).

Both control approaches have several limitations. For example, they require the child to look through a particular part of the spectacle lens to receive a sufficient amount of treatment and because the spectacle lens is placed in front of the eye, the treatment area is limited by the size of the distance correcting aperture.

Such limitations make it difficult to improve spectacle lens designs for myopia control based on reducing peripheral hyperopic defocus or accommodative lag.

Based on the increasing global prevalence of myopia and the need for myopia control spectacle lens products that can achieve better efficacy than current spectacle lenses, our team at the Brien Holden Vision Institute is currently testing new spectacle lens approaches, which does not require the wearer to look through a certain portion of the lens.
KEY PERSONNEL

Dr Cathleen Fedtke
(Project Manager) Dipl. Ing. (FH), PhD, FAAO

Dr Cathleen Fedtke graduated from the School of Optometry at the University of Applied Sciences in Germany (Aalen) in 2006, before completing her PhD at the Brien Holden Vision Institute and the University of New South Wales (UNSW) in Sydney, Australia, in 2011. Her PhD topic specialised in the development of a new clinical instrument (the BHVI-EyeMapper), which, being dedicated to measure global refraction profiles, can be of particular application to better understand and monitor myopia progression. Since the completion of her PhD, she has worked at the Brien Holden Vision Institute as Research Fellow (now Senior Research Fellow).

Dr Fedtke has several publications in peer reviewed journals, is a co-inventor of patents relating to myopia and instrumentation, and has presented at national and international conferences.
She is also a Fellow of the American Academy of Optometry (AAO), a Visiting Fellow of the School of Optometry and Vision Science at UNSW and a member of the Association for Research in Vision and Ophthalmology (ARVO).
TECHNOLOGY

The Brien Holden Vision Institute has several patent applications in the field of controlling myopia progression with spectacle lenses.

References

1. 'Eyewear Market worth over $180 bn by 2024: Global Market Insights', Nasdaq Global Newswire. Accessed on 20/02/2018 at: https://globenewswire.com/news-release/2016/03/28/823217/0/en/Eyewear-Market-Size-forecast-to-reach-USD-165-Billion-by-2022-Global-Market-Insights-Inc.html
2. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S, Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050, Ophthalmology, May 2016 Volume 123, Issue 5, Pages 1036–1042.